POAI Stock Overview
Predictive Oncology Inc., a science-driven company that applies artificial intelligence to support the discovery and development of optimal cancer therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Predictive Oncology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.76 |
| 52 Week High | US$7.12 |
| 52 Week Low | US$1.12 |
| Beta | 1.29 |
| 1 Month Change | -8.13% |
| 3 Month Change | -38.25% |
| 1 Year Change | -50.97% |
| 3 Year Change | -90.93% |
| 5 Year Change | -98.65% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| POAI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 31.3% | -0.5% | 1.6% |
| 1Y | -51.0% | -1.0% | 25.1% |
Return vs Industry: POAI underperformed the US Medical Equipment industry which returned -1.1% over the past year.
Return vs Market: POAI underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| POAI volatility | |
|---|---|
| POAI Average Weekly Movement | 14.1% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: POAI's share price has been volatile over the past 3 months.
Volatility Over Time: POAI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 35 | Raymond Vennare | www.predictive-oncology.com |
Predictive Oncology Inc., a science-driven company that applies artificial intelligence to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development.
Predictive Oncology Inc. Fundamentals Summary
| POAI fundamental statistics | |
|---|---|
| Market cap | US$7.15m |
| Earnings (TTM) | -US$13.98m |
| Revenue (TTM) | US$1.78m |
4.0x
P/S Ratio-0.5x
P/E RatioIs POAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POAI income statement (TTM) | |
|---|---|
| Revenue | US$1.78m |
| Cost of Revenue | US$634.80k |
| Gross Profit | US$1.15m |
| Other Expenses | US$15.13m |
| Earnings | -US$13.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.44 |
| Gross Margin | 64.34% |
| Net Profit Margin | -785.58% |
| Debt/Equity Ratio | 1.8% |
How did POAI perform over the long term?
See historical performance and comparison